Management of Worsening RLS After Semaglutide Use and Weight Loss

Critical Initial Assessment

The American Academy of Sleep Medicine recommends checking serum iron studies immediately, ideally in the morning after avoiding iron-containing supplements for at least 24 hours, and iron supplementation if ferritin ≤75 ng/mL or transferrin saturation <20% 1, 2, 3
Review all current medications for RLS-exacerbating agents including antihistamines, serotonergic medications, antidopaminergic agents, lithium, and assess for untreated obstructive sleep apnea, alcohol, and caffeine use 1, 2, 4

Initiate alpha-2-delta ligands as first-line therapy, with a strong recommendation and moderate certainty of evidence: gabapentin enacarbil, pregabalin, or gabapentin 1, 2, 3
The American Academy of Sleep Medicine recommends gabapentin enacarbil, starting at lower doses and titrating to therapeutic range, typically 600-1200 mg once daily in the evening 1, 2
Pregabalin is recommended, starting at 75 mg and titrating to 150-450 mg daily, with superior bioavailability 1, 3
Gabapentin is recommended, starting at 300 mg and titrating up to 1800-2400 mg/day divided into multiple doses 1, 3

If ferritin ≤75 ng/mL or transferrin saturation <20%, the American Academy of Sleep Medicine recommends oral ferrous sulfate or IV ferric carboxymaltose, with a conditional or strong recommendation and moderate certainty of evidence 1, 2, 3
Oral ferrous sulfate is recommended, with standard dosing and monitoring for constipation, the most common side effect 1, 2
IV ferric carboxymaltose is recommended, particularly effective in RLS even with normal serum iron studies 1, 3

The American Academy of Sleep Medicine specifically recommends against dopamine agonists, levodopa, and cabergoline, due to high augmentation risk or low certainty of evidence 1, 2, 3, 7

Extended-release oxycodone and other low-dose opioids are conditionally recommended, particularly effective for refractory cases, with evidence showing relatively low abuse risk in appropriately screened patients 1, 3
Bilateral high-frequency peroneal nerve stimulation is conditionally recommended, a non-pharmacological alternative with initial success in short-term studies 1, 3

Reassess in 4-6 weeks after initiating alpha-2-delta ligands and iron supplementation to evaluate symptom response, and consider dose titration or adding second-line agents if inadequate response 1, 2, 3
Monitor for side effects of alpha-2-delta ligands, including dizziness and somnolence, which may increase fall risk, particularly in older adults 1, 3
Recheck iron studies in 3-6 months if supplementation was initiated, as improvement in brain iron stores may lag behind serum normalization 3